Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
YTTRIUM [Y-90] CITRATE
CIS bio International
37-370 MBq/ml
Suspension for Injection
1999-03-19
IRISH MEDICINES BOARD ACT 1995, AS AMENDED MEDICINAL PRODUCTS (CONTROL OF PLACING ON THE MARKET) REGULATIONS, 2007, AS AMENDED PA0677/013/001 Case No: 2056589 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to CIS BIO INTERNATIONAL BP 32, 91192 GIF-SUR-YVETTE CEDEX, FRANCE an authorisation, subject to the provisions of the said Regulations, in respect of the product YTTRIUM ( 90 Y) COLLOID CIS BIO INTERNATIONAL, COLLOID SUSPENSION FOR LOCAL INJECTION. REFERENCE: YMM-1 the particulars of which are set out in the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 19/03/2009. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 14/07/2010_ _CRN 2056589_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Yttrium ( 90 Y) Colloid CIS bio international, colloid suspension for local injection. Reference: YMM-1 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Yttrium ( 90 Y) Citrate : 37-370 MBq/ml at calibration date Yttrium ( 90 Y) is a pure beta radiation emitter (maximum beta energy = 2.25 MeV). The half-life is 64 hours. The stable daughter is zirconium. For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Suspension for local injection. Clear and colourless suspension. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Therapeutic irradiation of synovial hypertrophy of the knee Read the complete document